Time filter

Source Type

Chen L.,Shandong University of Traditional Chinese Medicine | Wang K.,Shandong University of Traditional Chinese Medicine | Yu S.,Shandong University of Traditional Chinese Medicine | Lai L.,Peoples Hospital of Shouguang | And 3 more authors.
Renal Failure

Parathyroidectomy (PTx) and medical treatments are both recommended for reducing serum intact parathyroid hormone (iPTH) and curing secondary hyperparathyroidism (sHPT) in patients with chronic kidney disease (CKD), but their therapeutic effects on long-term mortality are not well-known. Thus, we aim to assess such therapeutic effect of PTx. Electronic literatures published on Pubmed, Embase, and Cochrane Central Register of Controlled Trials in any language until 27 November 2015 were systematically searched. All literatures that compared outcomes (survival rate or mortality rate) between PTx-treated and medically-treated CKD patients with sHPT were included. Finally, 13 cohort studies involving 22053 patients were included. Data were extracted from all included literatures in a standard form. The outcomes of all-cause and cardiovascular mortalities were assessed using DerSimonian and Laird’s random effects model. We find PTx-treated versus medically-treated patients had a 28% reduction in all-cause mortality and a 37% reduction in cardiovascular mortality. Thus, PTx versus medical treatments might reduce the risks of all-cause and cardiovascular mortalities in CKD patients with sHPT. Further studies with prospective and large-sample clinical trials are needed to find out the real effect of PTx and to assess whether mortality rates differ among patterns of PTx. © 2016 Informa UK Limited, trading as Taylor & Francis Group. Source

Ma Q.-F.,Peoples Hospital of Shouguang | Yao Z.-W.,Chongqing Medical University | Shan T.-X.,Peoples Hospital of Shouguang
Journal of Clinical Rehabilitative Tissue Engineering Research

BACKGROUND: Frost founded the theory of bone remodeling intervention, named sequential application, which administrate a promoting bone drug followed by an inhibitor of bone resorption. OBJECTIVE: According to the bone remodeling intervention theory, to investigate the effects of sequential application of estrogne and simvastatin on osteoporosis in ovariectomized rats. METHODS: Totally 40 SD male rats with 3-month-old were randomly divided into ovariectomized group and normal control group. In the ovariectomized group, double ovaries of rats were removed. In the normal control group, only the hypogastrium skins of rats were exposed. At 1 month after operation, the ovariectomized group were randomly allocated into sequential estradiol benzoate and simvastatin (sequential group), estrogen group and ovariectomized control group, and received medicine intervention as follows: coherent group: subcutaneous injected estradiol benzoate (0.1 mg/kg) per triduum for 2 weeks, followed by intragastric administrated simvastatin (5 mg/kg per day) for 2 weeks, the medication was removed for 5 weeks, and then intragastric administrated simvastatin (5 mg/kg per day) for 2 weeks; estrogen group: subcutaneous injected estradiol benzoate (0.1 mg/kg) per triduum for 11 weeks; in the ovariectomized control group, rats were given animal feeds only. After 11 weeks, the bone mineral density (BMD) was measured by double X-ray densitometry, and interleukin-6 (IL-6) and osteocalcin levels were detected by radioimmunoassay. RESULTS AND CONCLUSION: The BMD and osteocalcin levels were greater in treated groups than the ovariectomized control group (P < 0.05); especially higher in the sequential group than the estrogen group (P < 0.05). Meantime, the expression of IL-6 in the treated groups were degraded compared to the ovariectomized control group (P < 0.05), which was lower in the sequential group than the estrogen group (P < 0.05). The results demonstrated that sequential application of estrogen and simvastatin can prevent osteoporosis by inhibiting bone resorption and improving bone formation. Source

Duan L.-M.,Daqing Oil Field General Hospital | Yu H.-Y.,Daqing Oil Field General Hospital | Li Y.-L.,Peoples Hospital of Shouguang | Jia C.-J.,Peoples Hospital of Shouguang
Bioorganic and Medicinal Chemistry

A series of novel 2-(4-(1H-tetrazol-5-yl)-1H-pyrazol-1-yl)-4-(4-phenyl)thiazole derivatives, 6(a-o) were designed, synthesized and evaluated for inhibitory activity against human PDE3A and PDE3B. In PDE3 assay, entire set of targeted analogs showed considerable inhibition of PDE3A (IC50 = 0.24 ± 0.06-16.42 ± 0.14 μM) over PDE3B (IC50 = 2.34 ± 0.13-28.02 ± 0.03 μM). Among the synthesized derivatives, compound 6d exhibited most potent inhibition of PDE3A with IC50 = 0.24 ± 0.06 μM than PDE3B (IC50 = 2.34 ± 0.13 μM). This compound was further subjected for evaluation of cardiotonic activity (contractile and chronotropic effects) in comparison with Vesnarinone. Results showed that, it selectively modulates the force of contraction (63% ± 5) rather than frequency rate (23% ± 2) at 100 μM. Docking study of above compound was also carried out in the active site of PDE3 protein model to give proof to the mechanism of action of designed inhibitor. Further, in sub-acute toxicity experiment in Swiss-albino mice, it was found to be non-toxic up to 100 mg/kg dose for 28 days. © 2015 Published by Elsevier Ltd. Source

Discover hidden collaborations